Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited) Updates 2025 expected revenue range to $1.5 to 2.5 billion Expects ...

Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited)Updates 2025 expected revenue range to $1.5 to 2.5 billionExpects to ...

Up to 21 million people contract norovirus each year in the U.S. alone, the CDC says.

Moderna Inc. (NYSE: MRNA) has revised its sales projections for 2025, lowering expectations due to sluggish demand for its ...

Pershing Square Capital Management LP propuso un acuerdo para fusionar una filial recientemente creada con Howard Hughes ...

The company now expects revenue for 2025 to fall between $1.5 billion and $2.5 billion, a steep reduction from its previous ...

US stocks saw a decline on Monday as investors continued to unload key tech shares that have been driving the bull market.

And regular polling carried out by YouGov suggests adults are increasingly likely to say that vaccines have harmful side ...

Moderna says it has become the first company in the pharma sector with phase 3 data on a combined vaccine for both COVID-19 and influenza and will soon be ready to discuss “next steps” with ...

Nvidia ( NVDA -3.00%), the king of AI stocks, battled Apple in a struggle to claim the title of the world's largest public ...

Companies from Johnson & Johnson to Eli Lilly, Amazon and Nvidia are announcing health-related deals at the JPMorgan Health ...

Press Release Prudentia Sciences, an AI-powered technology platform for life sciences announced today its public launch, supported by $7 million in funding. The funding round was led by GV, with ...